Oculis Holding AG (OCS) Non-Current Deferred Tax Liability (2021)

Oculis Holding AG's (OCS) quarterly Non-Current Deferred Tax Liability came in at $11929.5 in Q4 2021.

Oculis Holding AG (OCS) Non-Current Deferred Tax Liability (2021) Analysis & Trends

Oculis Holding AG's Non-Current Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $11929.5 for Q4 2021.

On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $11929.5 in Q4 2021; TTM through Dec 2021 was $11929.5, a N/A change from a year earlier, with the FY2021 full-year figure at $12037.8, changed N/A from the prior year.
Non-Current Deferred Tax Liability was little changed at $11929.5 in Q4 2021 per OCS's latest filing.
Across five years, Non-Current Deferred Tax Liability topped out at $11929.5 in Q4 2021 and bottomed at $11929.5 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn

Download Data

Date	Value
Dec 31, 2021	11,929.52
Dec 31, 2021	11,929.52